611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Pool Chemicals Harm Thousands Every SummerAre Diets High in Processed Foods a Recipe for Obesity?Lupus Takes Bigger Toll on Longevity for BlacksScientists Spot Unexpected Player in FibromyalgiaAnthrax Is a Risk on Every ContinentAHA News: More Clues to the Genetics Behind an Inherited Cholesterol DisorderSuspect Your Child Has an Ear Infection? There May Soon Be an App for ThatLyme Disease Now a Threat in City Parks Health Tip: Treating a Charley HorseMore Back-to-Back Heat Waves Will Come With Climate ChangeParents, Here's How to Protect Your Child During Measles OutbreaksAHA News: Dangerous Blood Clots May Be the Latest Risk From 'Bad' CholesterolAre You Running Short on Iron?1 in 4 American Workers Struggles With Back PainInjured Lungs Can Be Regenerated for Transplant: StudyKeeping Your Summer Fun on Sound FootingMore Active Lupus Linked to Childhood EventsSigns of Rheumatoid Arthritis Can Show Up Long Before DiagnosisSummer Is Tough for Asthma SufferersHepatitis A Infections Soaring: CDCIs the County You Call Home a Potential Measles Hotspot?'Zap' Ear Clip May Ease A-FibTake Steps to Prevent a StrokeDoes Removing Your Appendix Put You at Risk for Parkinson's?Potentially Blinding Shingles of the Eye on the RisePsoriasis, Mental Ills Can Go Hand in HandAfter Concussions, Some Ex-Athletes Show Key Marker for Brain Disease: StudyWindow for Safe Use of Clot-Buster Widens for Stroke PatientsAn Antibiotic Alternative? Using a Virus to Fight BacteriaDo Adults Need a Measles Booster Shot?Military Tourniquets Might Save Kids' Lives During School ShootingsWell Water's Spillover Effect: Heart Damage?AHA News: Helping Asian-Americans Fight Their Hidden Heart RisksSunscreen Chemicals Enter Bloodstream at Potentially Unsafe Levels: Study'Ringing in the Ears' May Drive Some to the Brink of SuicideBlood Test Might Diagnose Chronic Fatigue SyndromeAsthma Inhalers Incorrectly Used by Most Kids in StudyDevice Helps Doctors Select Lungs for TransplantBenlysta Approved for Children With LupusIn a World First, Drone Delivers Kidney for TransplantHigh Measles Rates Mean Kids, Adults Need Proper Vaccination: CDCParents, Protect Your Kids as Measles Outbreaks SpreadWork Stress, Poor Sleep, High Blood Pressure a Deadly TrioFor Obese People, Commuting by Car Can Be a Killer: StudyHealth Tip: Tick RemovalHalf of Older Dialysis Patients Die Within a Year, Study FindsIs Peanut Allergy 'Immunotherapy' Causing More Harm Than Good?Long-Term Antibiotic Use May Up Women's Odds for Heart TroubleSalmonella Outbreak Tied to Pre-Cut Melons Expands to More Than 100 CasesAs U.S. Measles Cases Hit New High, Experts Warn the Disease Can Be Deadly
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Gene Therapy for Sickle Cell Takes Another Step Forward

HealthDay News
by By Amy Norton
HealthDay Reporter
Updated: Dec 4th 2018

new article illustration

TUESDAY, Dec. 4, 2018 (HealthDay News) -- A new gene therapy shows early promise against sickle cell anemia, researchers say.

The therapy targets the genetic flaw that causes sickle cell. In a small group of patients, researchers said the therapy appears safe and effective enough to keep moving forward into larger trials.

"We've been talking about using gene therapy for sickle cell anemia for years. Now it's finally coming of age," said Dr. John Tisdale, a scientist with the U.S. National Institutes of Health who is leading the ongoing research.

Sickle cell anemia is an inherited disease that mainly affects people of African, South American or Mediterranean descent. In the United States, about 1 in 365 black children is born with the condition, according to the NIH.

It arises when a person inherits two copies of an abnormal hemoglobin gene -- one from each parent. Hemoglobin is an oxygen-carrying protein within red blood cells.

When those cells contain "sickle" hemoglobin, they become crescent-shaped, rather than disk-shaped. They tend to be sticky and can clot -- causing symptoms such as fatigue and shortness of breath.

Many people with sickle cell also suffer bouts of severe pain due to poor blood circulation. Over time, the disease can damage organs throughout the body, leading to complications like kidney disease and stroke.

"It's a devastating disease," Tisdale said. "People often die early, in their 40s."

He presented the preliminary results this week at the American Society of Hematology's annual meeting, in San Diego.

There are treatments, such as the cancer drug hydroxyurea, which can help prevent severe pain and certain other complications. But the medications don't change the course of the disease.

There is one way to "fix" it, Tisdale said: a bone marrow transplant.

The procedure destroys a person's existing bone marrow stem cells -- which are producing the faulty red blood cells -- and replaces them with stem cells from a healthy donor.

The problem, Tisdale said, is that the donor has to be a genetic match (usually a sibling) who is free of sickle cell.

"That covers about 10 percent of patients," he said. "We need something for the other 90 percent."

That's where gene therapy could come in. Tisdale explained the basics: First, doctors remove a supply of blood-forming stem cells from the patient, before using chemotherapy to wipe out the remaining stem cells.

Next, they use a modified virus to deliver a "therapeutic" gene into the extracted stem cells. The gene is an "anti-sickling" version of the beta globulin gene, which is mutated in sickle cell.

Those genetically modified stem cells are then infused back into the patient -- with the aim of repopulating the body with normal red blood cells.

Tisdale's team initially treated seven patients with severe sickle cell who'd suffered complications from the disease. The gene therapy did produce new red blood cells, but at fairly low levels. So the researchers tweaked the procedure, and tested it in six other patients.

Of those patients, four had been followed for about three months on average as of May 2018. By that point, all had at least as many normal red blood cells as sickle-affected cells.

"We're also seeing a resolution of anemia and pain," Tisdale said.

The short-term side effects included fever caused by a drop in white blood cells, inflammation in the mouth, and chest pain.

This is not the first report of gene therapy being used for sickle cell. Last year, French researchers described the case of a teenage boy who was doing well 15 months after receiving gene therapy. Tisdale said that approach was very similar to the one his team used.

So far, research has focused on people with severe sickle cell.

But ultimately, the hope is to use gene therapy earlier in the course of the disease to prevent complications, said Dr. Caterina Minniti, director of the Montefiore Medical Center's Sickle Cell Center for Adults in New York City.

Minniti, who was not involved in the research, called the early results "very exciting."

Still, she cautioned that it will be a while before the approach is available for widespread use. With any gene therapy, Minniti noted, there are always questions about the long-term "stability" of the inserted gene, and whether it could have any unintended effects in the body.

But overall, she said, the outlook for sickle cell patients is improving. A new drug for preventing complications, called Endari (L-glutamine), received U.S. approval last year, and others are on the way.

"The development of therapies has dramatically accelerated in recent years," Minniti said.

Research presented at meetings is usually considered preliminary until published in a peer-reviewed medical journal.

More information

The U.S. National Heart, Lung, and Blood Institute has more on sickle cell anemia.